- Home
- APLM vs MI Comparison
APLM vs MI Comparison
Compare APLM & MI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- MI
- Stock Information
- Founded
- APLM 2016
- MI 2009
- Country
- APLM United States
- MI Hong Kong
- Employees
- APLM N/A
- MI N/A
- Industry
- APLM Blank Checks
- MI Catalog/Specialty Distribution
- Sector
- APLM Finance
- MI Consumer Discretionary
- Exchange
- APLM Nasdaq
- MI Nasdaq
- Market Cap
- APLM 6.9M
- MI N/A
- IPO Year
- APLM N/A
- MI N/A
- Fundamental
- Price
- APLM $5.33
- MI $2.50
- Analyst Decision
- APLM
- MI
- Analyst Count
- APLM 0
- MI 0
- Target Price
- APLM N/A
- MI N/A
- AVG Volume (30 Days)
- APLM 26.7K
- MI 16.5K
- Earning Date
- APLM 08-13-2025
- MI 01-01-0001
- Dividend Yield
- APLM N/A
- MI N/A
- EPS Growth
- APLM N/A
- MI N/A
- EPS
- APLM N/A
- MI 1.53
- Revenue
- APLM $198,000.00
- MI $740,701.00
- Revenue This Year
- APLM $415.15
- MI N/A
- Revenue Next Year
- APLM N/A
- MI N/A
- P/E Ratio
- APLM N/A
- MI $1.63
- Revenue Growth
- APLM N/A
- MI N/A
- 52 Week Low
- APLM $4.47
- MI $1.57
- 52 Week High
- APLM $35.98
- MI $10.29
- Technical
- Relative Strength Index (RSI)
- APLM 44.49
- MI 58.11
- Support Level
- APLM $5.33
- MI $2.03
- Resistance Level
- APLM $6.56
- MI $2.37
- Average True Range (ATR)
- APLM 0.54
- MI 0.17
- MACD
- APLM -0.05
- MI 0.04
- Stochastic Oscillator
- APLM 33.11
- MI 75.81
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.